{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:51:19Z","timestamp":1791355879222,"version":"4.3.1"},"reference-count":26,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2017,11,21]],"date-time":"2017-11-21T00:00:00Z","timestamp":1511222400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30CA016672"],"award-info":[{"award-number":["P30CA016672"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P01CA049639"],"award-info":[{"award-number":["P01CA049639"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2018,1]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>The degree of somatic hypermutation, determined as percent deviation of immunoglobulin heavy chain gene variable region sequence from the germline (<jats:italic><jats:styled-content style=\"fixed-case\">IGHV<\/jats:styled-content><\/jats:italic>%), is an important prognostic factor in chronic lymphocytic leukaemia (<jats:styled-content style=\"fixed-case\">CLL<\/jats:styled-content>). Currently, a cut\u2010off of 2% deviation or 98% sequence identity to germline in <jats:italic><jats:styled-content style=\"fixed-case\">IGHV<\/jats:styled-content><\/jats:italic> sequence is routinely used to dichotomize <jats:styled-content style=\"fixed-case\">CLL<\/jats:styled-content> patients into mutated and unmutated groups. Because dissimilar <jats:italic><jats:styled-content style=\"fixed-case\">IGHV<\/jats:styled-content><\/jats:italic>% cut\u2010offs of 1\u20135% were identified in different studies, we wondered whether no cut\u2010off should be applied and <jats:italic><jats:styled-content style=\"fixed-case\">IGHV<\/jats:styled-content><\/jats:italic>% treated as a continuous variable. We analysed the significance of <jats:italic><jats:styled-content style=\"fixed-case\">IGHV<\/jats:styled-content><\/jats:italic>% in 203 <jats:styled-content style=\"fixed-case\">CLL<\/jats:styled-content> patients enrolled on the original frontline fludarabine, cyclophosphamide and rituximab (<jats:styled-content style=\"fixed-case\">FCR<\/jats:styled-content>) trial with a median of 10\u00a0years follow\u2010up. Using the Cox Proportional Hazard model, <jats:italic><jats:styled-content style=\"fixed-case\">IGHV<\/jats:styled-content><\/jats:italic>% was identified as a continuous variable that is significantly associated with progression\u2010free (<jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content>) and overall survival (<jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content>) (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00\u00b7001). Furthermore, we validated this finding in 323 patients treated with <jats:styled-content style=\"fixed-case\">FCR<\/jats:styled-content> off\u2010protocol and in the total cohort (<jats:italic>n<\/jats:italic>\u00a0=\u00a0535). Multivariate analysis revealed a continuous trend. Higher <jats:italic><jats:styled-content style=\"fixed-case\">IGHV<\/jats:styled-content><\/jats:italic>% levels were incrementally associated with favorable <jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content> in both <jats:styled-content style=\"fixed-case\">FCR<\/jats:styled-content>\u2010treated cohorts (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00\u00b7001, both cohorts). Taken together, our data suggest that <jats:italic><jats:styled-content style=\"fixed-case\">IGHV<\/jats:styled-content><\/jats:italic>% is a continuous variable in <jats:styled-content style=\"fixed-case\">CLL<\/jats:styled-content> patients treated with <jats:styled-content style=\"fixed-case\">FCR<\/jats:styled-content>.<\/jats:p>","DOI":"10.1111\/bjh.15018","type":"journal-article","created":{"date-parts":[[2017,11,22]],"date-time":"2017-11-22T03:26:44Z","timestamp":1511321204000},"page":"33-40","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["The absolute percent deviation of <i><scp>IGHV<\/scp><\/i> mutation rather than a 98% cut\u2010off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab"],"prefix":"10.1111","volume":"180","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2735-168X","authenticated-orcid":false,"given":"Preetesh","family":"Jain","sequence":"first","affiliation":[{"name":"Department of Leukemia University of Texas, MD Anderson Cancer Center Houston TX USA"},{"name":"Division of Cancer Medicine at University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graciela M.","family":"Nogueras Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Department of Biostatistics University of Texas, MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmi","family":"Kanagal\u2010Shamanna","sequence":"additional","affiliation":[{"name":"Department of Hematopathology University of Texas, MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uri","family":"Rozovski","sequence":"additional","affiliation":[{"name":"Davidoff Cancer Center Beilinson Campus, Tel\u2010Aviv University Tel\u2010Aviv Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nawid","family":"Sarwari","sequence":"additional","affiliation":[{"name":"Department of Leukemia University of Texas, MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantine","family":"Tam","sequence":"additional","affiliation":[{"name":"Peter MacCallum Cancer Center Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William G.","family":"Wierda","sequence":"additional","affiliation":[{"name":"Department of Leukemia University of Texas, MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip A.","family":"Thompson","sequence":"additional","affiliation":[{"name":"Department of Leukemia University of Texas, MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Jain","sequence":"additional","affiliation":[{"name":"Department of Leukemia University of Texas, MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajyalakshmi","family":"Luthra","sequence":"additional","affiliation":[{"name":"Department of Hematopathology University of Texas, MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5304-7828","authenticated-orcid":false,"given":"Andres","family":"Quesada","sequence":"additional","affiliation":[{"name":"Department of Hematopathology University of Texas, MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Sanchez\u2010Petitto","sequence":"additional","affiliation":[{"name":"Department of Leukemia University of Texas, MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Ferrajoli","sequence":"additional","affiliation":[{"name":"Department of Leukemia University of Texas, MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Burger","sequence":"additional","affiliation":[{"name":"Department of Leukemia University of Texas, MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"Department of Leukemia University of Texas, MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[{"name":"Department of Leukemia University of Texas, MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"O'Brien","sequence":"additional","affiliation":[{"name":"Department of Leukemia University of Texas, MD Anderson Cancer Center Houston TX USA"},{"name":"Chao Family Comprehensive Cancer Center University of Irvine Irvine CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Keating","sequence":"additional","affiliation":[{"name":"Department of Leukemia University of Texas, MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1623-3613","authenticated-orcid":false,"given":"Zeev","family":"Estrov","sequence":"additional","affiliation":[{"name":"Department of Leukemia University of Texas, MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,11,21]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-09-600874"},{"key":"e_1_2_8_3_1","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1182\/blood.V128.22.2047.2047","article-title":"Chemoimmunotherapy for patients with chronic lymphocytic leukemia: MD anderson experience beyond FCR300","volume":"128","author":"Chihara D.","year":"2016","journal-title":"Blood"},{"key":"e_1_2_8_4_1","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1182\/asheducation.V2012.1.76.3806845","article-title":"Implications of new prognostic markers in chronic lymphocytic leukemia","volume":"2012","author":"Chiorazzi N.","year":"2012","journal-title":"Hematology\/The Education Program of the American Society of Hematology"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V94.6.1840"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-08-2696"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13940"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.04985.x"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI3009"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-2325"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404457"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.585529"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2011.12.005"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-11-4394"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V94.6.1848"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06928.x"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V100.4.1410.h81602001410_1410_1416"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2001-11-0066"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng0193-88"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.34"},{"key":"e_1_2_8_21_1","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1182\/blood.V128.22.233.233","article-title":"Five\u2010year experience with single\u2010agent ibrutinib in patients with previously untreated and relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic leukemia","volume":"128","author":"O'Brien S.M.","year":"2016","journal-title":"Blood"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.025338"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2009.12.020"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-09-667675"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-11-3485"},{"key":"e_1_2_8_26_1","first-page":"465","article-title":"Patients with chronic lymphocytic leukemia with mutated VH genes presenting with Binet stage B or C form a subgroup with a poor outcome","volume":"90","author":"Tobin G.","year":"2005","journal-title":"Haematologica"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00251-014-0812-3"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.15018","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.15018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T19:37:40Z","timestamp":1696016260000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.15018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,21]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["10.1111\/bjh.15018"],"URL":"https:\/\/doi.org\/10.1111\/bjh.15018","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,21]]},"assertion":[{"value":"2017-07-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-09-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-11-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}